2021 ECCO指南:溃疡性结肠炎的治疗—药物治疗

2021-10-12 欧洲克罗恩病和结肠炎组织 J Crohns Colitis

2021年10月,欧洲克罗恩病和结肠炎组织(ECCO)发布了溃疡性结肠炎的治疗—药物治疗指南。本文作为溃疡性结肠炎治疗指南的第1部分,主要针对药物治疗提供指导建议。

中文标题:

2021 ECCO指南:溃疡性结肠炎的治疗—药物治疗

英文标题:

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment

发布日期:

2021-10-12

简要介绍:

2021年10月,欧洲克罗恩病和结肠炎组织(ECCO)发布了溃疡性结肠炎的治疗—药物治疗指南。本文作为溃疡性结肠炎治疗指南的第1部分,主要针对药物治疗提供指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 ECCO指南:溃疡性结肠炎的治疗—药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9dff41c00220a125, title=2021 ECCO指南:溃疡性结肠炎的治疗—药物治疗, enTitle=ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment, guiderFrom=J Crohns Colitis, authorId=0, author=, summary=2021年10月,欧洲克罗恩病和结肠炎组织(ECCO)发布了溃疡性结肠炎的治疗&mdash;药物治疗指南。本文作为溃疡性结肠炎治疗指南的第1部分,主要针对药物治疗提供指导建议。, cover=https://img.medsci.cn/20211014/1634201208219_5579292.jpg, journalId=0, articlesId=null, associationId=685, associationName=欧洲克罗恩病和结肠炎组织, associationIntro=欧洲克罗恩病和结肠炎组织(ECCO)是一个快速成长和高度活跃的非营利性组织,代表超过31个国家15个协作组的1813名IBD专家,主要专注于炎症性肠病的研究。, copyright=0, guiderPublishedTime=Tue Oct 12 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年10月,欧洲克罗恩病和结肠炎组织(ECCO)发布了溃疡性结肠炎的治疗&mdash;药物治疗指南。本文作为溃疡性结肠炎治疗指南的第1部分,主要针对药物治疗提供指导建议。</span></p>, tagList=[TagDto(tagId=7365, tagName=溃疡性结肠炎)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=7365, guiderKeyword=溃疡性结肠炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=64568, appHits=459, showAppHits=0, pcHits=3307, showPcHits=64109, likes=0, shares=42, comments=16, approvalStatus=1, publishedTime=Thu Oct 14 16:57:52 CST 2021, publishedTimeString=2021-10-12, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Oct 14 16:51:08 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 03:29:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ECCO指南:溃疡性结肠炎的治疗—药物治疗.pdf)])
2021 ECCO指南:溃疡性结肠炎的治疗—药物治疗.pdf
下载请点击:
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1227701, encodeId=9edc122e70108, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:39:40 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227700, encodeId=55e0122e70023, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:26 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227699, encodeId=4c3d122e69980, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:16 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205027, encodeId=5de5120502e75, content=指导治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869f5565965, createdName=乐道, createdTime=Tue Mar 22 20:57:31 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204230, encodeId=bc5512042302f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Sun Mar 20 05:00:33 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-06-21 ms7000001591963948

    👍

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1227701, encodeId=9edc122e70108, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:39:40 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227700, encodeId=55e0122e70023, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:26 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227699, encodeId=4c3d122e69980, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:16 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205027, encodeId=5de5120502e75, content=指导治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869f5565965, createdName=乐道, createdTime=Tue Mar 22 20:57:31 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204230, encodeId=bc5512042302f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Sun Mar 20 05:00:33 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-06-21 ms7000001591963948

    挺好的

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1227701, encodeId=9edc122e70108, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:39:40 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227700, encodeId=55e0122e70023, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:26 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227699, encodeId=4c3d122e69980, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:16 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205027, encodeId=5de5120502e75, content=指导治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869f5565965, createdName=乐道, createdTime=Tue Mar 22 20:57:31 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204230, encodeId=bc5512042302f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Sun Mar 20 05:00:33 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-06-21 ms7000001591963948

    挺好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1227701, encodeId=9edc122e70108, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:39:40 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227700, encodeId=55e0122e70023, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:26 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227699, encodeId=4c3d122e69980, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:16 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205027, encodeId=5de5120502e75, content=指导治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869f5565965, createdName=乐道, createdTime=Tue Mar 22 20:57:31 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204230, encodeId=bc5512042302f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Sun Mar 20 05:00:33 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-22 乐道

    指导治疗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1227701, encodeId=9edc122e70108, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:39:40 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227700, encodeId=55e0122e70023, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:26 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227699, encodeId=4c3d122e69980, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79395492035, createdName=ms7000001591963948, createdTime=Tue Jun 21 10:38:16 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205027, encodeId=5de5120502e75, content=指导治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869f5565965, createdName=乐道, createdTime=Tue Mar 22 20:57:31 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204230, encodeId=bc5512042302f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Sun Mar 20 05:00:33 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-20 freegut

    学习了

    0

拓展阅读

2010 ACG实践指南:成人溃疡性结肠炎

美国胃肠病学院(ACG,American College of Gastroenterology) · 2010-01-01

2010 溃疡性结肠炎中医诊疗共识意见

中华中医药学会脾胃病分会 · 2010-06-01

溃疡性结肠炎中西医结合诊疗指南(草案,2010)

中国中西医结合学会消化系统疾病专业委员会 · 2011-02-01

2011NICE 结直肠癌高危人群(溃疡性结肠炎、克罗恩病、结直肠腺瘤患者)结肠镜监测指南

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-03-23

2012 CAG多伦多共识:成人重度溃疡性结肠炎患者的住院治疗

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2012-02-01

2012 ECCO/ESPGHAN 小儿溃疡性结肠炎管理指南

欧洲克罗恩病和结肠炎组织(ECCO,European Cron&#039;s and Colitis Organisation) · 2012-09-01